Product to be launched as Absorica in the US market in Q4 of 2012
Ranbaxy Laboratories Inc (RLI), a wholly-owned subsidiary of Ranbaxy Laboratories Ltd obtained the US FDA approval for Absorica. Absorica is a novel, patented brand formulation of the acne medication isotretinoin, developed by Cipher, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Cipher Pharmaceuticals, RLI is expected to launch Absorica in the US in Q4 2012; as per the agreement, Ranbaxy will pay royalties on net sales to Cipher.
“We are thrilled to make Absorica available as a valuable option for the dermatologists and patients who need treatment for severe recalcitrant nodular acne. Absorica is a critical milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy’s specialised dermatology sales force,” said Venkat Krishnan, Senior Vice President and Regional Director, Americas, Ranbaxy.
“Approval of Absorica represents our third FDA approval and most important milestone to date, reflecting the great work by our Scientific Affairs team at Cipher and our partner, Galephar Pharmaceutical Research. We look forward to working closely with our partner, Ranbaxy Laboratories Inc., in preparation for the upcoming U.S. launch of the product through its dermatology sales force,” said Larry Andrews, President and Chief Executive Officer, Cipher.
EP News Bureau — Mumbai